NCT06677190View on ClinicalTrials.gov

Belzutifan in Recurrent Clear Cell Ovarian Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

June 30, 2029

Conditions
Ovarian CancerOvarian Carcinoma
Interventions
DRUG

Belzutifan

A Hypoxia-Inducible Factor-2 alpha inhibitor, 40 mg immediate-release tablet, taken orally per protocol.

Trial Locations (2)

02215

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT06677190 - Belzutifan in Recurrent Clear Cell Ovarian Carcinoma | Biotech Hunter | Biotech Hunter